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The recent remarkable advances in multiple myeloma (MM)
therapy and outcomes have had mixed impact on patients with
adverse risk genetics, many of whom continue to have inferior
outcomes. This applies particularly to deletion of chromosome
17p13 [del(17p)], found in ≈10% of newly diagnosed MM (ND) and
at higher prevalence in advanced disease.1–5 The TP53 gene is
located within the minimally deleted region on 17p13, and is
thought to confer the adverse risk in a haploinsufﬁcient manner.6
The incidence of TP53 mutations in ND is ≈3% but also increases
with disease progression,7,8 and is associated with shorter
survival.9 Although TP53 mutations are uncommon in the absence
of del(17p), approximately one third of del(17p) MM patients are
reported to have a TP53 mutation, and this increases in refractory
disease to more than 50%.8,10
The prognostic impact of TP53 mutations in del(17p) MM
remains unresolved.2,10 We therefore carried out mutational
analysis of a series of MM patients who had ﬂuorescence in situ
hybridization (FISH)-identiﬁed del(17p) to correlate with clinical
outcomes.
Ethical approval was obtained from National Research Ethics
Service, London and informed consent in accordance with the
Declaration of Helsinki. Out of 286 patients (2009–2014) tested at
our centre using FISH on CD138+ bone marrow cells (Miltenyi
microbead isolation), del(17p) was detected in 10 out of 98
(10.2%) ND and 42 out of 188 (22.3%) relapsed patients. An
additional 6 patients were diagnosed with del(17p) at another
centre. Material was available for all 16 ND and 35 relapse patients
for mutational screening. In 23 patients, samples were available at
more than one time point (range 2–4). FISH analysis was
performed using standard probes.11 Genomic DNA was ampliﬁed
by polymerase chain reaction and screened for TP53 mutations in
exons 4–11 using denaturing high-performance liquid chromato-
graphy (DHPLC; Transgenomic, Glasgow, UK). Mutations were
veriﬁed by Sanger sequencing. Extended mutation testing was
performed on TP53-mutated samples using targeted next genera-
tion sequencing (NGS; Supplementary Materials). Clinical details
including treatment and disease response (2014 IMWG criteria)
were collated. Survival was estimated using Kaplan–Meier
methods, and differences were assessed by log-rank test, with
P-values o0.05 considered statistically signiﬁcant.
Eighteen different TP53 mutations were identiﬁed in 18 del(17p)
patients (35%) by DHPLC (Table 1). Consistent with other studies,10
most mutations occurred in exons 5, 6 and 8 encoding an integral
part of the p53 DNA binding domain. Seventeen (94%) were
single-nucleotide variants (SNVs), a similar spectrum to that
reported previously,10 although others have found deletions or
insertions.2 Seventeen SNVs were documented on the Interna-
tional Agency for Research on Cancer TP53 database; 14 (82%)
were missense mutations, two nonsense mutations and one
altered a splice site. Most were predicted to produce a non-
functional protein with o20% transcriptional activity. The
remaining mutation was a novel in-frame indel. In 83% of
samples, the variant allele frequency of the TP53 mutation was
450%, consistent with the known del(17p) in a signiﬁcant
proportion of cells. In three patients, additional low-level TP53
mutations were detected by NGS.
Twenty-three patients were tested more than once, including 8
patients with TP53 mutations, allowing us to explore the
chronology of these genetic events. TP53 mutations were
identiﬁed at multiple time points in 5 patients (Table 1). In case
1, the mutant level increased with disease progression, indicating
selection of the TP53-mutated clone. Case 11 showed clonal
evolution with the appearance of a FAM46C mutation at relapse.
Three patients (cases 3, 4 and 9) had consistently high mutant
levels at both time points. The subclonal nonsense mutation
detected in case 3 was only present in the ﬁrst mutated sample.
Thirteen of the 18 TP53-mutated patients (72%) were mutant-
positive in the ﬁrst sample analyzed (Figure 1a). In ﬁve this was at
diagnosis, indicating that 31% (5 of 16) of patients in this cohort
presented with both del(17p) and a TP53 mutation (cases 11,
15–18). However, this frequency may be an underestimate as
diagnostic samples were not available from two patients who
presented with del(17p), both of whom were TP53-mutated in a
subsequent relapse sample (cases 5 and 10). In six patients, it was
not possible to determine the chronology of their acquisition as
earlier FISH results or stored samples were not available. In cases 1,
3 and 6, TP53 mutations were only detected at relapse despite
mutational testing in earlier samples. Two of these patients also
only acquired the del(17p) at relapse. Of note, in both the
remaining two patients (cases 2 and 7), del(17p) acquisition clearly
preceded the TP53 mutation. Case 2 acquired del(17p) at ﬁrst
relapse 34 months post-diagnosis but only acquired a TP53
mutation at their fourth relapse 73 months post-diagnosis. Case 7
presented with del(17p), was mutant-negative at relapse
17 months later, but acquired a TP53 mutation at second relapse
26 months post-diagnosis. The chronology of FISH and mutational
testing for the 33 del(17p) patients without TP53 mutations is
shown in Supplementary Figure S1.
There was no difference in age at diagnosis or disease isotype
between TP53-mutated and non-mutated patients (Supplemen-
tary Table S1). Ten TP53-mutated patients (56%) also had at least
one other high-risk cytogenetic feature detected at some point in
their disease (t(4;14), t(14;16) or 1q gain; Table 1), but this
frequency was not signiﬁcantly different from the non-TP53-
mutated patients (56 vs 49%, P= 0.6). Ten TP53-mutated patients
(56%) also had additional mutations in previously reported
myeloma driver genes9,12 [DIS3(5), FAM46C(3), NRAS(3), KRAS(2),
TRAF3(2), FGFR3(1), PRDM1(1), ATM(1), BRAF(1) and PIK3CA(1)] and
most of these patients (7, 39%) had two or more additional
mutations (Table 1); in our series, the incidence of DIS3 mutations
(28%) appears higher.
Median overall survival (OS) from diagnosis was signiﬁcantly
shorter in TP53-mutated than in non-mutated patients (19 vs
74 months, P= 0.02; Supplementary Figure S2), as was median OS
from the time at which del(17p) was ﬁrst detected (8 vs 29 months,
Po0.01; Figure 1b). Median progression-free survival (PFS) from
ﬁrst detection of del(17p) was similar between the two groups (7
vs 12 months, P= 0.51; Supplementary Figure S3A), but the
acquisition of a TP53 mutation was associated with extremely poor
survival. Median PFS of patients from the time a mutation was ﬁrst
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detected was 5 months (Supplementary Figure S3B), and median
OS was 7 months (Figure 1c). In contrast, patients who remained
without detectable TP53 mutation had a median PFS of
11.5 months, with median OS 17 months, calculated from the
date of the last sample tested. There was thus a striking difference
in survival between patients with and without TP53 mutations.
These results conﬁrm that, although homozygous deletion of TP53
in MM is uncommon,3 inactivating TP53 mutations that are likely
to produce non-functional proteins are frequent in del(17p) MM.
TP53 haploinsufﬁciency in MM causes downstream p53 pathway
deregulation, altering the delivery of an apoptotic response,6 but
the biological consequence of the additional functional loss
conferred by mutation of the remaining allele remains unclear. In
this cohort, we observed that TP53 mutation usually occurred
after, or simultaneously with, allelic loss of 17p13, and conferred a
signiﬁcantly poorer prognosis for those patients with both
abnormalities. Bi-allelic inactivation of tumor suppressor genes,
including TP53, has been reported to drive relapse in MM. A recent
longitudinal study similarly identiﬁed that bi-allelic events leading
to complete TP53 inactivation resulted in the poorest prognosis at
relapse.13 Patients with the lowest levels of TP53 mRNA have also
been reported to have the worst clinical outcome.3,14 There is also
evidence of other mechanisms leading to p53 inactivation in MM,
including promoter methylation6 and aberrant expression and
function of p53-regulating miRNAs,15 thus investigation of TP53
mRNA and p53 protein levels may be warranted. Collectively our
results conﬁrm that, in the context of del(17p), acquisition of a
TP53 mutation on the other allele confers signiﬁcantly worse
clinical outcomes, and suggest that allelic loss of 17p13 likely
precedes such mutations. In the era of genomic medicine, there is
a case for routinely screening for TP53 mutations in del(17p) MM
to aid management decisions and direct these high-risk patients
towards alternative treatment strategies aimed at counteracting
the loss of tumor suppressor activity. Finally, the possibility of a
different target gene for del(17p) in patients who do not have
mutations of TP53 remains to be explored.
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Figure 1. Clinical impact of TP53 mutations. (a) Swimmer plot displaying the time of del(17p) FISH testing/detection and TP53 mutation
screening for each TP53-mutated patient. Kaplan–Meier curves for (b) overall survival (OS) from ﬁrst detection of del(17p) in patients with and
without TP53 mutations, and (c) from ﬁrst detection of the mutation in TP53-mutated patients compared to the last time point tested in non-
mutated patients. Dotted Line, TP53-mutated patients; solid line, non-TP53 patients. CI, 95% conﬁdence intervals; HR, hazard ratios.
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